Intellia Therapeutics

Many of us pursuing work in the biotechnology industry are inspired by a loved one who is living with a disease or the loss of someone in our community. Rare genetic and oncological and immunological diseases not only affect the people living with often debilitating and life-threatening symptoms, but these disorders also significantly impact their families, friends and caregivers.

Our researchers work tirelessly to harness the genome editing technology CRISPR/Cas9 for human therapeutic use. Jennifer Doudna, an Intellia co-founder, and Emmanuelle Charpentier were awarded the 2020 Nobel Prize in Chemistry for their pioneering work in CRISPR. We at Intellia are humbled to have a hand in making what we believe to be medical history. As a leader in this space, we take this responsibility to patients seriously.

We are employing a modular genome editing platform to create diverse in vivo and ex vivo pipelines, spanning a range of therapeutic indications. Guided by this full-spectrum approach, we are committed to making CRISPR/Cas9-based medicines a reality for patients suffering from genetic diseases and to creating novel engineered cell therapies for various cancers and autoimmune diseases.

Change life stories with genome editing therapies!

AWARDS
  • 2025 BPTW Badge - RBG.png
  • 2024 Best Places to Work
  • 2023 Best Places to Work
  • Intellia Top places to work
  • 2022 Best Places to Work
  • Intellia 2022 BG top places
40 Erie Street
Cambridge, MA 02139
Stock Symbol: NTLA
  • Featured Employer
At Intellia, we are revolutionizing medicine by harnessing the power of genome editing to develop CRISPR one-time treatments.
Tune into our podcast, Imagine the Possibilities, where we showcase Intellia talent across departments and take deep dives into all things culture and careers. We talk about career steps (and missteps), development, growth, and more. Just imagine the possibilities of what we can learn together.
Employee Testimonials
  • “Diversity, Equity and Inclusion is really important to me because in order to deliver our drugs to patients and achieve our goals, we need to create a work environment where everybody – regardless of race, gender, or sexuality – can come to Intellia and succeed here. That is what the Employee Resource Groups do, and that is why it is so important that Intellia has this program.”
    Peter C. Associate Scientist
  • “I lead the Community, Wellness, and Sustainability Cultural Ambassadors Team and am deeply passionate about the environment and wellness from a holistic point of view. As a team, we raise awareness on topics like plastic pollution, sustainable living, and climate change. We motivate others to adopt simple, yet impactful adjustments to their lifestyle and promote healthy work-life balance by offering weekly practices such as yoga, mindfulness and meditation.”
    Elena K, Sr Scientist, RNA Chemistry & Delivery Sciences
  • “There have been an immense number of opportunities for me to step up and make meaningful contributions to Intellia’s vision. I’ve been surrounded by career role models thoughout my time here. I learn from their career growth and apply those learnings to my own journey.”
    Ramsey M, Director, Delivery Sciences, Delivery Physics, and Biology
NEWS
BridgeBio secured approval for Attruby Friday, along with the all-important mortality benefit that could give the drug a significant boost in the market against Pfizer’s tafamidis and potentially Alnylam’s Amvuttra.
Analysts appear optimistic for Intellia’s gene editor nex-z, which showed a greater serum TTR reduction than Alnylam’s Amvuttra.
BioSpace takes a look at the headlines across a heavy earnings week for biotechs, checking in on Allogene, Rapport and more.
BioSpace has named 50 biopharma companies to its 2025 Best Places to Work list, including Moderna and Sutro Biopharma, whose executives share what makes their organizations special.
Jefferies analyst Maury Raycroft said in a note to investors that Thursday’s mid-stage readout pointed to the “unprecedented” complete response rate of Intellia’s investigational in vivo gene editing therapy in the disorder.
As the yearslong litigation over ownership of CRISPR gene editing continues, investors have forged ahead with funding the technology’s development by biopharma.
The trial, which is the first late-stage study of an in vivo CRISPR treatment in the U.S., will start by the end of 2023. Intellia’s NTLA-2001 is a treatment candidate for transthyretin amyloidosis cardiomyopathy.
The companies are expanding their long-standing CRISPR/Cas9 gene editing collaboration for the second time, now seeking to target neurological and muscular conditions.
Gene editing technologies are advancing rapidly in the clinic, with the potential first approval later this year, but challenges remain.
JOBS
  • Intellia 2024 Premier
  • Intellia 2024 Elite artwork
IN THE PRESS